News & Updates

Both the structured and targeted educational interventions for appropriate omeprazole prescribing in the primary care setting are effective in reducing the rates of inappropriate omeprazole prescription at Marine Parade Polyclinic in Singapore, a study has shown.

In patients with psoriatic arthritis (PsA) inadequately controlled by a tumour necrosis factor inhibitor (TNFi), combination treatment with guselkumab plus golimumab appears to yield clinically meaningful benefits only in those with elevated C-reactive protein levels, as shown in a study.

Daily use of topical finasteride 0.25% as monotherapy has resulted in significant increases in hair density and thickness for postmenopausal women with female-pattern hair loss (FPHL) treated in real-world settings, according to a retrospective study.

Use of antithrombotic agents at admission does not increase the risk of in-hospital mortality in patients with acute upper gastrointestinal bleeding (UGIB), according to a study, noting a protective trend overall and significant protection in antiplatelet users and nonvariceal bleeding.

Adding carboplatin to doxorubicin and cyclophosphamide, followed by taxane therapy, results in significant improvement in event-free survival (EFS) among patients with early-stage triple-negative breast cancer (TNBC), as shown in the PEARLY trial.

Treatment with upadacitinib, an oral Janus kinase (JAK)-selective inhibitor, continues to improve skin repigmentation through week 76 in patients with nonsegmental vitiligo (NSV), according to the phase III Viti-Up-1 and -2 studies presented at EADV 2026.

New drug applications approved by US FDA as of 1-15 October 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

New drug applications approved by US FDA as of 16-31 October 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Combination treatment with sacituzumab govitecan (SG) and pembrolizumab does not improve outcomes in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) unselected by programmed death-ligand 1 (PD-L1), as shown in a phase II trial.

A recent study has found no evidence of the noninferiority of low-dose aspirin (LDA) continuation over discontinuation during gastric endoscopic submucosal dissection (ESD) in patients with gastric mucosal neoplasms and low thrombotic risk.